PMParul Malhotra

Parul Malhotra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Parul Malhotra has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Snoring on the Cardiovascular System and its Treatment: Positive and Negative Effects of Continuous Positive Airway Pressure in Sleep Apnea

    by Thulasi Priya Jayaprakash, Olisaemeka D. Ogbue, Parul Malhotra, Radhika Akku, Safeera Khan

    Obstructive sleep apnea (OSA) is a common condition, and if not treated can be a significant risk factor for multiple comorbidities like hypertension (HTN), coronary artery disease (CAD), and congestive heart failure (CHF). The underlying pathophysiology involves coagulation and inflammatory pathways, including an overactive sympathetic nervous system. This ultimately causes hemodynamic changes and subclinical myocardial injuries. We reviewed the published literature about the impact of continuous positive airway pressure (CPAP) when used as a mode of treatment to reduce the OSA effects on cardiomyocytes. We found that the results were mixed, including both ill and good effects. The cardiac markers like N-terminal pro-brain natriuretic peptide (NT-proBNP) and atrial natriuretic peptide (ANP) were reduced, implying the decrease in the incidence of heart failure with CPAP treatment in a few of the studies. They also proved a significant decrease in harmful cardiovascular (CV) outcomes, while others concluded that CPAP therapy might be stressful on the heart, causing an elevation in cardiac troponin T levels. However, the impact on inflammatory markers is still indeterminate and needs more research in future.


  • Open Access

    Current Trends Featuring the Bridge Between Stroke and End-Stage Renal Disease: A Review

    by Radhika Akku, Thulasi Priya Jayaprakash, Olisaemeka D. Ogbue, Parul Malhotra, Safeera Khan

    The relationship between end-stage renal disease (ESRD) and cerebral stroke is graded and cumulative, having a significant impact on morbidity and mortality. Ischemic stroke is more prevalent than hemorrhagic stroke and both stroke types have modifiable and non-modifiable risk factors. The presence of risk factors such as hypertension, diabetes, and atrial fibrillation (AF) before stroke occurrence in dialysis patients has a significant impact on the outcomes such as a discharge to rehabilitation, in-hospital mortality with the worst prognosis when compared to the general population. ESRD patients with either peritoneal or hemodialysis (HD) are at increased risk of stroke than the general population, with a high mortality rate at the commencement of dialysis and gradually decreases. Primary and secondary prevention of risk factors plays a significant role in this susceptible population and helps to mitigate better treatment and outcomes. Our review article focuses on the mechanisms, outcomes, treatment, and preventive aspects of stroke in the ESRD population.


  • Open Access

    A Review of the Impact of Smoking on Inhaled Insulin: Would You Stop Smoking if Insulin Can Be Inhaled?

    by Parul Malhotra, Radhika Akku, Thulasi Priya Jayaprakash, Olisaemeka D. Ogbue, Safeera Khan

    High prevalence of diabetes and the need for tight glycemic control have been well established. With the invention of inhaled insulin, an alternate route has been explored and shows great promise. Inhaled insulin shows a similar physiologic response to subcutaneous insulin, with a faster onset of action, making it suitable for post-prandial hyperglycemia. This comes as a great relief, especially to those who are hesitant to use multiple injections in a day. Many factors affect insulin absorption, including device, particle size, airway patency. Another essential factor is smoking, which is prevalent among people with diabetes, as is in the non-diabetic population. Smoking increases the absorption of inhaled insulin, but it is not a straight fact, since acute smoking, passive smoking, chronic smoking - all have different effects on inhaled insulin. Furthermore, inhaled insulin is also affected by lung diseases. Most studies that have been conducted have included limited populations, thus questioning their generalisability. The studies from inception till 2020 have shown increased permeability of epithelial with acute smoking, change of epithelial layer back to normal after few weeks of smoking cessation, and reverting to chronic smoker levels with just one to two days of start in smoking. Data also suggests that smoking causes a reduction in insulin sensitivity, which could compensate for its increased absorption. Nicotine causes a decrease in the absorption of subcutaneous insulin, but its effect has not been seen on inhaled insulin. More studies, including diabetic smoker patients, need to be performed to give a specific set of variables. This would also add another reason to encourage smokers to quit smoking.

  • Open Access

    Biologic Therapies in Sarcoidosis and Uveitis: A Review

    by Olisaemeka D. Ogbue, Parul Malhotra, Radhika Akku, ThulasiPriya Jayaprakash, Safeera Khan

    Sarcoidosis and uveitis are chronic inflammatory conditions with potentially debilitating effects on quality of life. Steroids form the mainstay standard therapy in both conditions. Biologic agents are considered to be appropriate alternatives for treatment in steroid-refractory sarcoidosis and uveitis due to the role of tumor necrosis factor (TNF) in mediating the inflammatory cascade seen in both conditions. We performed a thorough literature search using PubMed to compare the extent of use, efficacy, and safety profile of individual anti-TNF agents in the management of these conditions. Our review consists of two systematic reviews with meta-analysis, thirteen observational studies, and fifteen case series/reports. Infliximab had the widest range of organ-system usage in extra-pulmonary sarcoidosis but is equivalent to adalimumab in terms of efficacy. In uveitis, adalimumab was found to be the most efficacious agent for maintaining disease remission in adults and children with chronic non-infectious uveitis. Etanercept was neither used widely, nor was it efficacious in the management of either condition. In terms of safety profile, biologic agents were found to be well tolerated and have a similar safety profile. More randomized clinical trials are needed to inform evidence-based use of biologic agents in these conditions.